Antibodies for
Immunohistochemistry
TAG-72 (B72.3)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45336 IMPATH TAG-72 RTU M (B72.3)
50 Tests
44393 TAG-72 RTU M (B72.3)
7 ml Ready To Use
44805 TAG-72 0,1 M (B72.3)
100 µl liquid Concentrated
44806 TAG-72 1 M (B72.3)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Lung Adenocarcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-TAG-72 (B72.3) is monoclonal antibody directed against a high molecular weight glycoprotein known as tumor-associated glycoprotein-72
(TAG-72). The antigen is expressed in a limited range of benign tissue but a wide range of adenocarcinomas.
Theantigenisusuallyexpressedbyadenocarcinomas,butisusuallynegativeinmesotheliomas.Studieshaveshownthatthisantibodyhas80%sensitivity
and93%specificityforpulmonaryadenocarcinoma.Therefore,TAG-72isausefulmarkertodistinguishbetweenmesotheliomaandadenocarcinoma.
However, falsepositive reactions canoccur so resultsmust be interpretedwith theutmost caution. This antibodymaybeuseful in thedifferentiationof
non-small cell carcinomas from small cell carcinomas of the lung. The combined use of anti-TAG-72 and anti-GCDFP-15 is valuable in the
diagnosis of apocrine carcinoma.
Pleura: Adenocarcinoma vs. Mesothelioma
TAG-72 Calretinin CK 5&6 D2-40 HBME-1 Caldesmon Ep-CAM E-cadherin TTF-1
CEA
Adenocarcinoma
+
-
-
-
-
-
+
+
+
+
Mesothelioma
-
+
+
+
+
+
-
-
-
-
Reference
1. Thor A, et al. Cancer Res. 1986; 46:3118.
2. Schlom J, et al. Tumormarker Oncology. 1987; 2:3.
3. Johnston WW, et al. Hum Pathol. 1986; 17:501-513.
4. Lundy J, et al. Ann Aurg. 1986; 203:399-402.
5. Kline TS, et al. Cancer. 1989; 63:2253-2256.
6. Chhieng DC, et al. Hum Pathol. 2003 Oct; 34(10):1016-21.
7. Ordonez NG. Am J Surg Pathol. 1998 Oct; 22(10):1203-14.
8. Osteen KG, et al. In J Gynecol Pathol. 1992 Jul; 11(3):216-20.
224
